<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240110060672N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-02-17</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Comparing the effectiveness of Cognitive Rehabilitation and Cognitive Behavioral Therapy (CBT) on reducing depressive symptoms and improving the quality of life in the elderly with Major Depressive Disorder (MDD)</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the effectiveness of Cognitive Rehabilitation and Cognitive Behavioral Therapy (CBT) on reducing depressive symptoms and improving the quality of life in the elderly with Major Depressive Disorder (MDD)</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>34</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/74937</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Other, Purpose: Treatment, Randomization description: This study is conducted as a double-blind study. The person responsible for assessing the elderly individuals based on the inclusion criteria and referring them to the main researcher will be unaware of the treatment assigned to each patient. Similarly, the trained person evaluating the effectiveness of the treatment will also be unaware of the type of treatment provided to the elderly. This process will be further explained in order to ensure double-blinding.

To achieve double-blinding, cards with codes written on them are used. These codes are based on a randomization table with balanced blocks that were designed in advance. The coordinator will have access to these cards and will distribute them to individuals who meet the entry criteria and have completed the informed consent. The cards will then be provided to the main researcher for future reference.

The main researcher or therapist will observe the letter written in front of each patient's code on the randomization table. If the letter A is written, cognitive rehabilitation intervention will be performed. If the letter B is written, cognitive behavioral therapy will be administered.

Before the intervention begins, the effectiveness of the treatment will be evaluated by a trained person who is unaware of the treatment assigned to each patient. This person will enter the results of each test, along with the corresponding number and name of each elderly individual, into Excel, Blinding description: This study is conducted as a double-blind study. The person responsible for assessing the elderly individuals based on the inclusion criteria and referring them to the main researcher will be unaware of the treatment assigned to each patient. Similarly, the trained person evaluating the effectiveness of the treatment will also be unaware of the type of treatment provided to the elderly. This process will be further explained in order to ensure double-blinding.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Major Depressive Disorder (MDD).</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Cognitive rehabilitation. Intervention 2: Intervention group 2: Cognitive Behavioral Therapy (CBT).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is -</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nafee Rasouli</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Motahari street, Hosseini rad</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1599953511</zip>
        <telephone>+98 21 8891 2928</telephone>
        <email>nafeerasouli@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nafee Rasouli</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Motahari street, Hosseinirad</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1599953511</zip>
        <telephone>+98 21 8891 2928</telephone>
        <email>nafeerasouli@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Diagnosis of major depression by semi-structured SCID interview
A score higher than 6 in the Geriatric Depression Scale (GDS)
Receiving antidepressants (SSRI)
At least 3 weeks have passed since the start of drug treatment
At least 55 years old
Education above seventh grade</inclusion_criteria>
      <agemin>55 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Major and minor cognitive impairment based on DSM-5
A score lower than 26 in the MoCA
Having psychotic disorders or brain damage</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Cognitive rehabilitation</i_keyword>
      <i_keyword>Intervention group 2: Cognitive Behavioral Therapy (CBT)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Depression symptoms. Timepoint: In three stages including: the beginning of the study (before the start of the intervention), immediately after the end of the intervention, 3 months after the end of the intervention. Method of measurement: Depression criteria of DSM-5 (SCID),  Geriatric Depression Scale (GDS).</prim_outcome>
      <prim_outcome>Quality of life. Timepoint: In three stages including: the beginning of the study (before the start of the intervention), immediately after the end of the intervention, 3 months after the end of the intervention. Method of measurement: The World Health Organization Quality of Life Persian questioner.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Executive function. Timepoint: In three stages including: the beginning of the study (before the start of the intervention), immediately after the end of the intervention, 3 months after the end of the intervention. Method of measurement: Trial making test, Verbal fluency.</sec_outcome>
      <sec_outcome>Attention and consentration. Timepoint: In three stages including: the beginning of the study (before the start of the intervention), immediately after the end of the intervention, 3 months after the end of the intervention. Method of measurement: Digit span (DS).</sec_outcome>
      <sec_outcome>Information processing speed. Timepoint: In three stages including: the beginning of the study (before the start of the intervention), immediately after the end of the intervention, 3 months after the end of the intervention. Method of measurement: Symbol Digit Modality Test (SDMT).</sec_outcome>
      <sec_outcome>Verbal memory. Timepoint: In three stages including: the beginning of the study (before the start of the intervention), immediately after the end of the intervention, 3 months after the end of the intervention. Method of measurement: Logical Memory (LM).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>grant</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-07-23</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences (IUMS), Shahid Hemmat Highway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
